Ethical Considerations of Myostatin Inhibitors

Why these questions matter now

For most of the last two decades, the ethics of blocking myostatin was a thought experiment. Animals with myostatin mutations, or with the protein blocked, carry much more muscle, and reviewers such as Yamada and colleagues (2012) warned that sport regulators should prepare for athletes trying the same biology. Human drugs kept stalling, so the debate stayed abstract.

That changed in 2026. In September 2026 the FDA approved apitegromab (Isembyld) for spinal muscular atrophy (SMA) in patients aged 2 and older who already take an SMN2-targeted treatment. The agency calls it the first SMA therapy that targets muscle loss directly. Two Phase 2 obesity trials (BELIEVE and COURAGE) have also tested myostatin-pathway antibodies as a way to keep muscle during weight loss on semaglutide. Once a drug class has accepted medical uses, questions about who should get it, and on what evidence, stop being hypothetical.

This page is an overview. Two child pages go deeper: one on competitive fairness and myostatin inhibition and one on WADA's rules for myostatin inhibitors. Questions specific to bodybuilding, such as how untested federations fit in, are covered in ethics in bodybuilding. For the drugs themselves, start with the myostatin inhibitors overview.

Therapy versus enhancement

In bioethics, enhancement usually means changing the body beyond what's needed to restore or keep health. A 2011 review by Oliveira and colleagues in the Brazilian Journal of Medical and Biological Research applies that framing to gene doping: methods built to treat disease, used by healthy people to perform better.

Myostatin drugs sit right on that line. Apitegromab treats a disease in which muscle loss is the problem. The obesity trials are less clear-cut:

• BELIEVE (507 adults with obesity, Nature Medicine, March 2026): at 48 weeks, lean mass fell 0.8% to 2.3% with bimagrumab plus semaglutide, compared with 4.7% to 6.9% on semaglutide alone.
• COURAGE (Regeneron, reported October 1, 2026): at 52 weeks, lean mass fell 5.8% and 4.2% at the two trevogrumab doses tested with semaglutide, versus 7.3% with semaglutide plus placebo.

Keeping muscle in someone losing weight on a prescription medicine looks like treatment. The same antibody in a lean, healthy lifter looks like enhancement. The molecule doesn't change; the person and the goal do.

Function is the weak point in the treatment case. In BELIEVE, SF-36 physical functioning scores were similar across groups at 48 weeks, with larger improvements only in the high-dose combination by week 72. If preserved lean mass doesn't translate into better health, calling it therapy gets harder to defend.

Safety enters the same calculation. The FDA notes an increased risk of fractures, including serious fractures, with Isembyld. In COURAGE, a triplet arm that added the activin A antibody garetosmab had more discontinuations and two deaths. Regeneron says it hasn't identified a causal link, and Medscape reports that only trevogrumab is moving forward. A risk that makes sense for a child with SMA is a different bargain for a healthy adult who wants more size.

Fairness in tested sport

The World Anti-Doping Code states its own ethical rationale. The 2027 Code, which takes effect January 1, 2027, says anti-doping "is primarily an ethical position based on a vision of the spirit of sport" and describes that spirit as "the ethical pursuit of athletic excellence through the dedicated perfection of each Athlete's natural talents." Under Article 4.3.1, WADA may consider listing a substance if it meets any two of these criteria:

1. It enhances, or has the potential to enhance, sport performance.
2. Its use represents an actual or potential health risk to the athlete.
3. Its use violates the spirit of sport.

As of October 2026, WADA's 2026 Prohibited List places myostatin and activin-pathway agents in section S4.3, prohibited at all times. Named examples include ACE-031 and bimagrumab. Follistatin is listed too, as are myostatin antibodies such as apitegromab. Because apitegromab is now both approved and named on the list, an athlete with SMA who needed it would have to apply for a Therapeutic Use Exemption under Article 4.4 of the Code.

The framework has critics. Bengt Kayser and colleagues (BMC Medical Ethics, 2007) argued that the "level playing field" rationale rests on "largely unsubstantiated assumptions" and that prohibition pushes use away from medical oversight. They proposed medically supervised enhancement instead. Oliveira and colleagues summarize WADA's case against gene doping as two arguments: unknown health risks, including possible changes passed to future generations, and fairness, since well-funded athletes would get access first. The competitive-fairness page covers natural genetic variation and the access question in more detail.

Consent with research-market products

Informed consent assumes a person can know what they're taking and what it might do. Research-market myostatin products make that hard. Vials sold online as "follistatin-344" or "ACE-031" have no published human data. The real ACE-031 trials were halted in 2011 after participants had minor nosebleeds and gum bleeding along with dilated blood vessels in the skin. The developers ended the program in May 2013, according to MDA Quest (our ACE-031 page has the trial details). Buyers have no way to confirm what a vial with that name contains.

Quality data from other peptides point the same way. A preprint (not yet peer-reviewed) by Mendias and Awan analyzed 6,441 independent test results for 14 gray-market peptides. Between 41.6% and 71.1% failed basic quality criteria, depending on the standard applied, and 15% of the 243 samples tested for endotoxin had measurable levels. None of the 14 compounds was a myostatin product, and the authors note the dataset isn't a random sample of the market. Even so, it shows how little a label guarantees.

This is the core consent problem. Apitegromab's fracture warning exists because the drug went through controlled trials; research-market buyers don't get even that much information. Users on peptide forums often frame self-experimentation as a personal choice. Kayser's group makes a related harm-reduction point: unsupervised use outside elite sport may expose more people to harm than elite doping does.

Gene doping with follistatin

WADA's section M3 bans gene and cell doping, including any nucleic acids that "may alter genome sequences and/or gene expression by any mechanism." Follistatin, a protein that binds myostatin, is the clearest myostatin example. Nationwide Children's Hospital ran an early Phase 1 trial of intramuscular AAV1 follistatin gene transfer in Becker muscular dystrophy and inclusion body myositis (NCT01519349), completed in 2017.

As of October 2026, two newer trials are listed. CALM-AF-AI (NCT07443826) is testing AAV-follistatin plus a VEGF plasmid for age-related muscle loss; it is recruiting and plans 12 participants. Minicircle's pilot of klotho plus follistatin plasmid therapy in 14 healthy adults (NCT07285629), with sites in Austin and Roatán, Honduras, is listed as completed in April 2026. Neither has posted results.

Minicircle's earlier work is where the consent and oversight concerns are most concrete. MIT Technology Review reported in 2023 that the company was testing follistatin gene therapy in Próspera, a Honduran special economic zone with its own health rules. Leigh Turner, a bioethicist at UC Irvine, told the magazine that such places may not put many resources into overseeing medical research. The company's own preprint reports 43 volunteers with small increases in fat-free mass and no serious treatment-related adverse effects. The study was open-label and company-run, and ethics approval came from its partner clinic's review board.

Detection adds to the fairness problem. Yamada and colleagues wrote in 2012 that the adverse effects of gene doping, its effect on human performance and the means of detecting it were all still unknown. If a modification can't be detected, a ban on it depends on athletes choosing to comply.

What to watch next

• The full COURAGE paper (in press at The Lancet) and Regeneron's planned Phase 2 trial of trevogrumab in older adults with obesity and low muscle mass or strength.
• Whether any athlete's Therapeutic Use Exemption request for apitegromab becomes public, which would show how anti-doping bodies handle an approved drug named on S4.3.
• Results from the follistatin gene therapy trials above, and whether regulators outside special economic zones scrutinize offshore gene therapy offered to healthy adults.